Charlotte Derpoorter

Mrs. Charlotte Derpoorter

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2020 in Cells
Verified
Journal Article
Open access
PDF file
ADAraceli Brugge-Oostende Diez-Fraile
Araceli Brugge-Oostende Diez-Fraile
JCJoke De Ceulaer
Joke De Ceulaer
CDCharlotte Derpoorter
Charlotte Derpoorter
CSChristophe Spaas
Christophe Spaas
TBTom De Backer
Tom De Backer
TLTim Lammens
Tim Lammens
Head and neck cancer (HNC), the seventh most common form of cancer worldwide, is a group of epithelial malignancies affecting sites in the upper aerodigestive tract. The 5-year overall survival for patients with HNC has stayed around 40–50% for decades, with mortality being attributable mainly to late diagnosis and recurrence. Recently, non-coding RNAs, including tRNA halves, YRNA fragments, microRNAs (miRNAs), and long non-coding RNAs (lncRNAs), have been identified in the blood and saliva of patients diagnosed with HNC. These observations have recently fueled the study of their potential use in early detection, diagnosis, and risk assessment. The present review focuses on recent insights and the potential impact that circulating non-coding RNA evaluation may have on clinical decision-making in the management of HNC.

1 November 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CDCharlotte Derpoorter
Charlotte Derpoorter
VBVictoria Bordon
Victoria Bordon
GLGeneviève Godelieve Laureys
Geneviève Godelieve Laureys
FHFilomeen Haerynck
Filomeen Haerynck
TLTim Lammens
Tim Lammens
Primary immunodeficiencies (PIDs) are a heterogeneous group of inherited disorders affecting one or multiple components of the innate and/or adaptive immune system. Currently, over 300 underlying genetic defects have been discovered. The most common clinical findings in patients with PIDs are infections, autoimmunity and malignancies. Despite international efforts, the cancer risk associated with PIDs, given the heterogeneous character of this group of diseases, is difficult to estimate. The diverse underlying mechanisms of cancer in PID add another layer of complexity. Treatment of cancer within a context of PID is complicated by serious toxicities and long-term effects, including second malignancies. This review will focus on the little-known crossroad between PID and cancer genes and the value thereof for directing future research on our understanding of cancer in PID and for the identification of early cancer biomarkers in PID patients.

1 August 2022 in Pediatric Hematology and Oncology
Verified
Journal Article
Open access
JBJutte van der Werff Ten Bosch
Jutte van der Werff Ten Bosch
EHEva Hlaváčková
Eva Hlaváčková
CDCharlotte Derpoorter
Charlotte Derpoorter
UFUte Fischer
Ute Fischer
FSFrancesco Saettini
Francesco Saettini
SBSimon Bomken
Simon Bomken
Inborn errors of immunity (IEI) are a group of disorders caused by genetically determined defects in the immune system, leading to infections, autoimmunity, autoinflammation and an increased risk of malignancy. In some cases, a malignancy might be the first sign of an underlying IEI. As therapeutic strategies might be different in these patients, recognition of the underlying IEI by the pediatric hemato-oncologist is important. This article, written by a group of experts in pediatric immunology, hemato-oncology, pathology and genetics, aims to provide guidelines for pediatric hemato-oncologists on how to recognize a possible underlying IEI and what diagnostic tests can be performed, and gives some consideration to treatment possibilities.

Verified
Journal Article
Open access
PDF file
ADAraceli Brugge-Oostende Diez-Fraile
Araceli Brugge-Oostende Diez-Fraile
JCJoke De Ceulaer
Joke De Ceulaer
CDCharlotte Derpoorter
Charlotte Derpoorter
CSChristophe Spaas
Christophe Spaas
TBTom De Backer
Tom De Backer
TLTim Lammens
Tim Lammens
The 5-year relative survival for patients with head and neck cancer, the seventh most common form of cancer worldwide, was reported as 67% in developed countries in the second decade of the new millennium. Although surgery, radiotherapy, chemotherapy, or combined treatment often elicits an initial satisfactory response, relapses are frequently observed within two years. Current surveillance methods, including clinical exams and imaging evaluations, have not unambiguously demonstrated a survival benefit, most probably due to a lack of sensitivity in detecting very early recurrence. Recently, liquid biopsy monitoring of the molecular fingerprint of head and neck squamous cell carcinoma has been proposed and investigated as a strategy for longitudinal patient care. These innovative methods offer rapid, safe, and highly informative genetic analysis that can identify small tumors not yet visible by advanced imaging techniques, thus potentially shortening the time to treatment and improving survival outcomes. In this review, we provide insights into the available evidence that the molecular tumor fingerprint can be used in the surveillance of head and neck squamous cell carcinoma. Challenges to overcome, prior to clinical implementation, are also discussed.

23 October 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CDCharlotte Derpoorter
Charlotte Derpoorter
KVKarl Vandepoele
Karl Vandepoele
ADAraceli Diez‐Fraile
Araceli Diez‐Fraile
KVKatrien Vandemeulebroecke
Katrien Vandemeulebroecke
BWBram De Wilde
Bram De Wilde
GLGeneviève Laureys
Geneviève Laureys

14 June 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
ZRZhiyao Ren
Zhiyao Ren
JVJolien Vanhooren
Jolien Vanhooren
CDCharlotte Derpoorter
Charlotte Derpoorter
BMBarbara De Moerloose
Barbara De Moerloose
TLTim Lammens
Tim Lammens
Risk stratification using genetics and minimal residual disease has allowed for an increase in the cure rates of pediatric acute myeloid leukemia (pedAML) to up to 70% in contemporary protocols. Nevertheless, ∼30% of patients still experience relapse, indicating a need to optimize stratification strategies. Recently, long noncoding RNA (lncRNA) expression has been shown to hold prognostic power in multiple cancer types. Here, we aimed at refining relapse prediction in pedAML using lncRNA expression. We built a relapse–related lncRNA prognostic signature, named AMLlnc69, using 871 transcriptomes of patients with pedAML obtained from the Therapeutically Applicable Research to Generate Effective Treatments repository. We identified a 69 lncRNA signature AMLlnc69 that is highly predictive of relapse risk (c-index = 0.73), with area under the receiver operating characteristic curve (AUC) values for predicting the 1-, 2-, and 3-year relapse-free survival (RFS) of 0.78, 0.77, and 0.77, respectively. The internal validation using a bootstrap method (resampling times = 1000) resulted in a c-index of 0.72 and AUC values for predicting the 1-, 2-, and 3-year RFS of 0.77, 0.76, and 0.76, respectively. Through a Cox regression analysis, AMLlnc69, nucleophosmin mutation, and white blood cell at diagnosis were identified as independent predictors of RFS. Finally, a nomogram was build using these 2 parameters, showing a c-index of 0.80 and 0.71 after bootstrapping (n = 1000). In conclusion, the identified AMLlnc69 will, after prospective validation, add important information to guide the management of patients with pedAML. The nomogram is a promising tool for easy stratification of patients into a novel scheme of relapse-risk groups.